These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 7821191

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effect of long-term treatment with a new aldose reductase inhibitor, (2S,4S)-6-fluoro-2',5'-dioxospiro-[chroman-4,4'-imidazolidine]-2-carbox amide (SNK-860), on peripheral neuropathy in streptozotocin-induced diabetic rats.
    Kato N, Mizuno K, Matsubara A, Nakano K, Kurono M, Yagihashi S.
    J Diabetes Complications; 1994; 8(1):27-32. PubMed ID: 8167384
    [Abstract] [Full Text] [Related]

  • 3. Effects of 15-month aldose reductase inhibition with fidarestat on the experimental diabetic neuropathy in rats.
    Kato N, Mizuno K, Makino M, Suzuki T, Yagihashi S.
    Diabetes Res Clin Pract; 2000 Oct; 50(2):77-85. PubMed ID: 10960717
    [Abstract] [Full Text] [Related]

  • 4. An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia.
    Frank RN, Amin R, Kennedy A, Hohman TC.
    Arch Ophthalmol; 1997 Aug; 115(8):1036-47. PubMed ID: 9258227
    [Abstract] [Full Text] [Related]

  • 5. The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
    Shindo H, Tawata M, Aida K, Onaya T.
    J Clin Endocrinol Metab; 1992 Feb; 74(2):393-8. PubMed ID: 1370506
    [Abstract] [Full Text] [Related]

  • 6. Preventive effect of long-term aldose reductase inhibition (ponalrestat) on nerve conduction and sural nerve structure in the spontaneously diabetic Bio-Breeding rat.
    Sima AA, Prashar A, Zhang WX, Chakrabarti S, Greene DA.
    J Clin Invest; 1990 May; 85(5):1410-20. PubMed ID: 2110189
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of long-term aldose reductase inhibition on development of experimental diabetic neuropathy. Ultrastructural and morphometric studies of sural nerve in streptozocin-induced diabetic rats.
    Yagihashi S, Kamijo M, Ido Y, Mirrlees DJ.
    Diabetes; 1990 Jun; 39(6):690-6. PubMed ID: 2140802
    [Abstract] [Full Text] [Related]

  • 9. Effect of aldose reductase inhibition on nerve conduction velocity and resistance to ischemic conduction block in experimental diabetes.
    Price DE, Airey CM, Alani SM, Wales JK.
    Diabetes; 1988 Jul; 37(7):969-73. PubMed ID: 3133261
    [Abstract] [Full Text] [Related]

  • 10. Effect of a potent new aldose reductase inhibitor, (5-(3-thienyltetrazol-1-yl)acetic acid (TAT), on diabetic neuropathy in rats.
    Hotta N, Kakuta H, Fukasawa H, Koh N, Sakakibara F, Nakamura J, Hamada Y, Wakao T, Hara T, Mori K.
    Diabetes Res Clin Pract; 1995 Feb; 27(2):107-17. PubMed ID: 7607048
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Interactions between essential fatty acid, prostanoid, polyol pathway and nitric oxide mechanisms in the neurovascular deficit of diabetic rats.
    Cameron NE, Cotter MA, Hohman TC.
    Diabetologia; 1996 Feb; 39(2):172-82. PubMed ID: 8635669
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Overt diabetic neuropathy: repair of axo-glial dysjunction and axonal atrophy by aldose reductase inhibition and its correlation to improvement in nerve conduction velocity.
    Sima AA, Prashar A, Nathaniel V, Bril V, Werb MR, Greene DA.
    Diabet Med; 1993 Mar; 10(2):115-21. PubMed ID: 8458187
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effects of a new aldose reductase inhibitor, (2S, 4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-ca rboxamid e (SNK-860), on the slowing of motor nerve conduction velocity and metabolic abnormalities in the peripheral nerve in acute streptozotocin-induced diabetic rats.
    Mizuno K, Kato N, Matsubara A, Nakano K, Kurono M.
    Metabolism; 1992 Oct; 41(10):1081-6. PubMed ID: 1328819
    [Abstract] [Full Text] [Related]

  • 17. Prevention of defects of axonal transport and nerve conduction velocity by oral administration of myo-inositol or an aldose reductase inhibitor in streptozotocin-diabetic rats.
    Mayer JH, Tomlinson DR.
    Diabetologia; 1983 Nov; 25(5):433-8. PubMed ID: 6197336
    [Abstract] [Full Text] [Related]

  • 18. Effect of the aldose reductase inhibitor tolrestat on nerve conduction velocity, Na/K ATPase activity, and polyols in red blood cells, sciatic nerve, kidney cortex, and kidney medulla of diabetic rats.
    Raccah D, Coste T, Cameron NE, Dufayet D, Vague P, Hohman TC.
    J Diabetes Complications; 1998 Nov; 12(3):154-62. PubMed ID: 9618071
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Nodal Na(+)-channel displacement is associated with nerve-conduction slowing in the chronically diabetic BB/W rat: prevention by aldose reductase inhibition.
    Cherian PV, Kamijo M, Angelides KJ, Sima AA.
    J Diabetes Complications; 1996 Nov; 10(4):192-200. PubMed ID: 8835918
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.